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Abstracts / Biol Blood Marrow Transplant 21 (2015) S240eS265 S253(10.3%) were attributed to bacterial infection. Risk factors
associated with higher risk of bacterial infections included
age < 2 years at transplantation (p¼0.001), use of PB
(p¼0.038), myeloablative conditioning (p¼0.027), mis-
matched or unrelated donor (p¼ 0.002), family donors other
than identical siblings (p¼0.046), use of TPN (p¼0.046), and
morphine use for more than 5 days (p¼0.011) due to
signiﬁcant mucositis. In a multivariate analysis; age at
transplantation < 2 years (HR¼6.834; 95% CI 1.528-30.572;
p¼0.0119) was the only factor associated with higher risk for
bacterial infection post HSCT.
Conclusion: Bacterial infections are common following
allogeneic HSCT in children and adolescents not receiving
antibiotic prophylaxis and are associatedwith signiﬁcant risk
of mortality. Children below 2 years of age are at higher risk.
We have prospectively implemented an antibiotic prophy-
laxis regimen in an effort to decrease bacterial infections.352
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Introduction: Cytomegalovirus (CMV) infection is a known
complication following allogeneic hematopoietic stem cell
transplantation (HSCT). The method and duration of CMV
monitoring are center-dependent, and no standards on the
effective duration of CMV surveillance are clearly reported in
the literature especially in areas with high CMV exposure.
Patients and Methods: We retrospectively reviewed the
medical records of all consecutive patients who received
allogeneic HSCT between January 2008 and April 2014 at
King Hussein Cancer Center (KHCC) in Jordan. The CMV
infectionwasmonitored using pp65 antigenemia test weekly
from time of neutrophil engraftment until day 100 post
transplantation. Treatment with gancyclovir was initiated
when two consecutive positive antigenemia tests of more
than two cells per 250 WBC were documented. All patients
received leukoﬁltered and irradiated blood products.
Results: A total of 200 patients were identiﬁed, with median
age of 9 year (2 months-27 year). Sixty percent (n¼119) were
males. One hundred and nineteen patients (60%) had non-
malignant diseases. Peripheral blood (PB) was the stem cell
source in 110 (55%), 69 (34.5%) received bone marrow and 21
patients (10.5%) received cord blood. Sixty nine percent
received myeloablative conditioning (n¼137), 26% reduced
intensity (n¼52) and 5% no conditioning regimen (n¼11).
Ninety-one percent (n¼182) were matched-related (140
were HLA identical siblings and 42 were other family
donors). Ninety three percent of our patients (n¼186) and
83% of donors (n¼166) were CMV sero positive. Thirty-ﬁve
patients (17.5%) needed preemptive therapy for CMV
reactivation at a median of 33 days (14-70) following
transplantation. The median number of cells was one cell per
250 WBC (1-2298). Ten patients continued to have positive
CMV antigenemia on day 70, and 3 on day 100, while only
one patient had new episode of CMV reactivation after 70
days post transplantation. Two patients (1%) developed CMVdisease (pneumonitis and colitis). In univariate analysis,
patients who received ATG (p¼0.005), non-sibling related
donors (p¼0.037), mismatched or unrelated donor
transplants (p¼0.007), PB (p¼0.019), and myeloablative
conditioning (p¼0.004) were at higher risk for developing
CMV reactivation. In multivariate analysis; ATG use
(HR¼2.87; 95% CI 1.026-8.025; p¼0.0445) and the use of
mismatched related or unrelated donor (HR¼11.11; 95% CI
1.87-66.67, p¼0.0081) was associated with increased risk of
CMV reactivation.
Conclusion: The incidence of CMV reactivation following
allogeneic HSCT in children and adolescents within high
CMV exposure population is low. Shortening the duration of
CMV surveillance may be feasible. Use of ATG in the
preparative regimen and those receiving mismatched or
alternative donor transplants are at the highest risk for CMV
reactivation.353
Predictors and Outcomes of Intensive Care Utilization in
Patients Undergoing Allogeneic Hematopoietic Stem Cell
Transplant at Mayo Clinic, Florida
Demetria Ileana Jacks 1, Erin Mobley 2, Colleen Thomas 3,
Laura Finn 2, James Foran 2, Vivek Roy 2. 1 Hematology/
Oncology, Mayo Clinic, Jacksonville, FL; 2 Bone Marrow
Transplant, Mayo Clinic, Jacksonville, FL; 3 Health Sciences
Research, Mayo Clinic, Jacksonville, FL
To understand predictors and outcomes of ICU admissionwe
conducted a retrospective study of consecutive patients
undergoing allogeneic HCTover a 10 year period 1/2002 - 12/
2012. Information about patient demographics, disease
characteristics, disease status, co-morbidities, conditioning
regimen, donor characteristics and ICU interventions were
collected. Single and multivariable analysis was used to
assess associations between various characteristics and
outcomes. Survival probabilities were estimated using the
Kaplan-Meier method.
118 patients underwent ﬁrst transplant. Median age was
51 (range 20-72); 81% had leukemia. 39 (33%) patients were
admitted to the ICU within the ﬁrst 100 days; 22 within 14
days of transplant. Median survival of these patients was 54
days (95% CI 14-189) compared to 4.5 years for patients not
admitted to ICU. In single variable analysis, TBI (p¼0.04),
URD (p¼0.03), mismatched donor (p¼0.009)*, and not in CR
(p<0.001)* were associated with increased likelihood of
ICU admission (*signiﬁcance in multivariable analysis).
HCT-CI score was not found to be associated with ICU
admission.
Increased risk of death in ICU patients was associated with
male sex (p<0.001), HCT-CI deﬁned liver dysfunction
(p¼0.003) and vasopressor administration (p¼0.020) in
single variable analysis. Adjusting for sex (HR¼4.63),
vasopressor administration (HR 4.54, p¼0.001) and number
of ICU interventions within 48 hours of admission (HR 3.48
[>1 vs 0], p¼ 0.026) were associated with increased risk of
death. APACHE score was not associated.
Compared to females, male patients had higher rates of
myeloablative regimens (71% v 56%), TBI (48% v 33%), URD
HCT (76% v 44%) and vasopressor use (33% v 24%) as well as
lower rates of CR (19% v 28%) at time of transplant.
ICU admissionwas associated with an increased risk of death
(HR¼ 3.70, 95% CI 2.26-6.06, p<0.001). ICU survivors tended
to have worse long-term outcomes. Among 18 patients alive
at day 90, 12 survived to one year (67%) compared to 61 out
of 79 (77%) who never required ICU admission (p¼0.84).
Further analysis to understand the causes of worse outcomes
